The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Gut Microbiota-Mediated Drug Interactions between Lovastatin and Antibiotics
Abstract
Orally administered drugs may be metabolized by intestinal microbial enzymes before absorption into the blood. Accordingly, coadministration of drugs affecting the metabolic activities of gut microbes (e.g., antibiotics) may lead to drug-drug interactions (DDI). In this study, gut microbiota-mediated DDI were investigated by studying the pharmacokinetics of lovastatin in antibiotic-treated rats. Incubation of lovastatin with human and rat fecalase preparations produced four metabolites, M1 (demethylbutyryl metabolite), M4 (hydroxylated metabolite), M8 (the active hydroxy acid metabolite), and M9 (hydroxylated M8), indicating involvement of the gut microbiota in lovastatin metabolism. The plasma concentration-time profiles of M8 were compared after oral administration of lovastatin to control rats or those treated with either ampicillin (100 mg/kg) or an antibiotic mixture consisting of cefadroxil (150 mg/kg), oxytetracycline (300 mg/kg), and erythromycin (300 mg/kg). Pharmacokinetic analyses indicated that systemic exposure to M8 was significantly lower in antibiotic-treated rats compared with controls. In addition, fecal M8 formation decreased by 58.3 and 59.9% in the ampicillin- and antibiotic mixture-treated rats, respectively. These results suggested that antibiotic intake may reduce the biotransformation of orally administered drugs by gut microbiota and that the subsequent impact on microbiota metabolism could result in altered systemic concentrations of either the intact drug and/or its metabolite(s).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“hydroxylation of lovastatin, albeit less well-characterized in terms of specific enzyme involvement, in an animal model following coadministration of an antibiotic that resulted in a more extreme depletion of the microbiota”
From Gut reactions: Breaking down xenobiotic–microbiome interactions (2019) · cites this paper as Yoo et al., 2014
Citations
Cites
Gut flora in health and disease
Guarner, F., & Malagelada, J. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12489-0 · Cited by 3,480
The gastrointestinal microbiota as a site for the biotransformation of drugs
Sousa, T., Paterson, R., Moore, V., Carlsson, A., Abrahamsson, B., & Basit, A. W. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.009 · Cited by 618
Transporters and Drug-Drug Interactions: Important Determinants of Drug Disposition and Effects
König, J., Müller, F., & Fromm, M. F. (2013) · Pharmacological Reviews · doi:10.1124/pr.113.007518 · Cited by 595
Metabolism of Foreign Compounds by Gastrointestinal Microorganisms
Scheline, R. R. (1973) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06622-0 · Cited by 513
Inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy
Lindenbaum, J., Rund, D. G., Butler, V. P., Tse-Eng, D., & Saha, J. R. (1981) · New England Journal of Medicine · doi:10.1056/nejm198110013051403 · Cited by 423
Bowey, E. A., Adlercreutz, H., & Rowland, I. R. (2003) · Food and Chemical Toxicology · doi:10.1016/s0278-6915(02)00324-1 · Cited by 391
Digoxin-Inactivating Bacteria: Identification in Human Gut Flora
Dobkin, J. F., Saha, J. R., Butler, V. P., Neu, H. C., & Lindenbaum, J. (1983) · Science · doi:10.1126/science.6836275 · Cited by 259
Metabolism of Xenobiotics of Human Environments
Croom, E. L. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-415813-9.00003-9 · Cited by 258
Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
Neuvonen, P. J., & Jalava, K.-M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90167-8 · Cited by 238
Biotransformation of lovastatin
Wang, R. W., Kari, P. H., Lu, A. Y. H., Thomas, P. E., Guengerich, F. P., & Vyas, K. P. (1991) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(91)90551-s · Cited by 196
Developing a metagenomic view of xenobiotic metabolism
Haiser, H. J., & Turnbaugh, P. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.07.009 · Cited by 186 · cited 1×
“However, orally administered xenobiotics may also be metabolized by gut microbial enzymes before being absorbed from the gastrointestinal tract into the blood (Scheline, 1973; Sousa et al., 2008; Haiser and Turnbaugh, 2013).”
BackgroundSaad, R., Rizkallah, M. R., & Aziz, R. K. (2012) · Gut Pathogens · doi:10.1186/1757-4749-4-16 · Cited by 167
Molecular Insights into Microbial β-Glucuronidase Inhibition to Abrogate CPT-11 Toxicity
Roberts, A. B., Wallace, B. D., Venkatesh, M. K., Mani, S., & Redinbo, M. R. (2013) · Molecular Pharmacology · doi:10.1124/mol.113.085852 · Cited by 140
Neuvonen, P. J. (2010) · PubMed · Cited by 132
The Role of Gut Microbiota in Drug Response
Wilson, I. D., & Nicholson, J. K. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168173 · Cited by 115
Cometabolism of Microbes and Host: Implications for Drug Metabolism and Drug-Induced Toxicity
Li, H., & Jia, W. P. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.157 · Cited by 92
Lovastatin: A New Cholesterol‐Lowering Agent
Krukemyer, J. J., & Talbert, R. L. (1987) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1987.tb03524.x · Cited by 86
Jin, M. J., Kim, U., Kim, I., Kim, Y., Kim, D., Han, S. B., Kim, D., Kwon, O., & Yoo, H. H. (2010) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2010.511549 · Cited by 70
Fecal metabolic activities of herbal components to bioactive compounds
Lee, D.-S., Kim, Y.-S., Ko, C., Cho, K., Bae, H.-S., Lee, K.-S., Kim, J.-J., Park, E., & Kim, D.-H. (2002) · Archives of Pharmacal Research · doi:10.1007/bf02976558 · Cited by 62
Choi, J., Hong, S.-W., Kim, Y., Jang, S., Kim, N., Han, M.-J., & Kim, D. (2011) · Journal of Ginseng Research · doi:10.5142/jgr.2011.35.3.301 · Cited by 53
Vyas, K. P., Kari, P. H., Pitzenberger, S. M., Halpin, R. A., Ramjit, H. G., Arison, B. H., Murphy, J. S., Hoffman, W. F., Schwartz, M. S., & Ulm, E. H. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07606-8 · Cited by 47
Isoherranen, N., Lutz, J. D., Chung, S. P., Hachad, H., Levy, R. H., & Ragueneau, I. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300192g · Cited by 44
General Principles of Antimicrobial Therapy
Wilkowske, C. J., & Hermans, P. E. (1987) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)62333-7 · Cited by 32
Vyas, K. P., Kari, P. H., Prakash, S. R., & Duggan, D. E. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)07608-1 · Cited by 31
Inhibition of CYP3A by Erythromycin: In Vitro-In Vivo Correlation in Rats
Zhang, X., Galinsky, R. E., Kimura, R. E., Quinney, S. K., Jones, D. R., & Hall, S. D. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.028290 · Cited by 22
General Principles of Antimicrobial Therapy
Wilkowske, C. J. (1991) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)61582-1 · Cited by 20
Complete assignment of 1H and 13C NMR data of pravastatin derivatives
Bacher, M., Baumann, K., Knapp, H., Steck, A., & Teibl, S. (2008) · Magnetic Resonance in Chemistry · doi:10.1002/mrc.2312 · Cited by 10
Cited by
Sorted by citations
Gut microbiome interactions with drug metabolism, efficacy, and toxicity
Wilson, I. D., & Nicholson, J. K. (2017) · Translational Research · doi:10.1016/j.trsl.2016.08.002 · Cited by 656
Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes
Li, W., & Duffy, A. J. (2017) · Journal of Nutrition · doi:10.3945/jn.116.240754 · Cited by 433
Gut reactions: Breaking down xenobiotic–microbiome interactions
Clarke, G., Sandhu, K. V., Griffin, B. T., Dinan, T. G., Cryan, J. F., & Hyland, N. P. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.015768 · Cited by 319
The influence of gut microbiota on drug metabolism and toxicity
Li, H., Jiaojiao, H., & Jia, W. P. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1121234 · Cited by 279
The influence of the gut microbiota on the bioavailability of oral drugs
Zhang, X., Han, Y., Huang, W., Jin, M., & Gao, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.013 · Cited by 250
Metadata
- Authors
- Yoo, D.-H., Kim, I. S., Van Le, T. K., Jung, I.-H., Yoo, H. H., & Kim, D.-H.
- Affiliations
- Kyung Hee University (KR)
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 42
- Issue
- 9
- Pages
- 1508-1513
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2163951374
- Cited by
- 158
- References
- 27
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 15 · 2023: 16 · 2022: 14 · 2021: 15 · 2020: 22 · 2019: 17 · 2018: 13 · 2017: 9 · 2016: 8 · 2015: 9 · 2014: 1
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug Metabolism and Disposition (publishedVersion)
- PubMed (publishedVersion)
- The Royal Society of Chemistry’s Journals, Books and Databases (The Royal Society of Chemistry) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- lovastatin, drug-drug interactions, gut microbiota, drug metabolism, ampicillin, cefadroxil, oxytetracycline, erythromycin, pharmacokinetics, oral drug absorption
- MeSH terms
- Administration, Oral, Adult, Animals, Anti-Bacterial Agents, Biotransformation, Drug Interactions, Feces, Female, Humans, Lovastatin, Male, Middle Aged, Rats, Sprague-Dawley, Gastrointestinal Tract, Rats, Young Adult, Microbiota
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
